Comparative Pharmacology
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPANOVA versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
EPANOVA vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% is a crystalline amino acid solution combined with electrolytes and dextrose. Amino acids provide substrates for protein synthesis, dextrose supplies calories to minimize protein catabolism, and electrolytes maintain acid-base and electrolyte balance.
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion: 500-1000 mL administered over 1-2 hours per day, adjusted based on electrolyte and fluid requirements. Typical adult dose provides 2.75% amino acids and 5% dextrose with electrolytes.
None Documented
None Documented
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Amino acids: 15-30 min (rapid redistribution). Dextrose: 1-2 h. Clinical context: continuous infusion maintains steady state.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal: >95% of infused amino acids and dextrose metabolites excreted as urea, CO2, and water. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution